Market News & Trends
Avacta Group Announces Positive Outcome of Proof-of-Concept Study
Avacta Group plc recently announced its initial study with Glythera Limited, the developer of next-generation antibody drug conjugates, has concluded successfully. Following this study, the…
OWKIN Closes $11-Million Financing for AI in Drug Development
OWKIN, a predictive analytics company that utilizes transfer learning to accelerate drug discovery and development, recently announced an $11-million Series A funding round, led by…
Colorcon Transforms the Sugar Coating Process With a New Opadry System
Colorcon Inc. recently announces an exciting process development for sugar coated pharmaceutical tablets with the launch of Opadry® SGR, Rapid Sugar Film Coating System. This…
Sanofi to Acquire Bioverativ for $11.6 Billion
Sanofi and Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders, have entered into a definitive agreement under which…
Next Breath Announces Injectable Extractable & Leachable Services
Next Breath, a division of AptarGroup, is pleased to announce the extension of their cGMP analytical services to include development services for injectable delivery systems,…
CTI BioPharma to Receive $10-Million Milestone
CTI BioPharma recently announced that it expects to receive a $10-million milestone payment in February 2018 from Teva Pharmaceutical Industries related to the achievement of…
Pandion Therapeutics Announces $58-Million Financing to Advance Tissue-Specific Immune Modulator Drugs
Pandion Therapeutics, Inc. recently announced the completion of a $58-million Series A financing. This funding will be used to advance its initial drug programs for…
Syndax Announces Clinical Collaboration With Genentech
Syndax Pharmaceuticals Inc. recently announced a new clinical collaboration with Genentech, a member of the Roche Group. As part of the collaboration, the two companies…
ARCA Biopharma Announces Completion of GENETIC-AF Phase 2B Clinical Trial
ARCA Biopharma, Inc. recently announced the completion of patient follow-up for GENETIC-AF, a Phase 2B, double-blind, superiority clinical trial evaluating Gencaro (bucindolol hydrochloride) as a…
Teneobio Announces Strategic Alliance With TESARO
Teneobio, Inc., a next-generation multi-specific antibody therapeutics company, recently announced the initiation of a research collaboration and licensing agreement with TESARO, Inc., an oncology-focused biopharmaceutical…
ProQR & Galapagos Announce Research Collaboration
ProQR Therapeutics N.V. recently announced it has entered into a research collaboration agreement with Galapagos N.V. Under the agreement, the two companies will work together…
CymaBay Therapeutics Receives $5-Million Milestone Payment
CymaBay Therapeutics, Inc. recently announced it has received a $5-million milestone payment from Kowa Pharmaceuticals America for the initiation of a study evaluating the pharmacokinetics…
NANOBIOTIX Partners With the Providence Cancer Institute
Nanobiotix recently announced it will begin a preclinical collaboration with Providence Cancer Institute to study Nanobiotix's lead product, NBTXR3, a first-in-class nanoparticle designed for direct…
GeoVax & Vaxeal to Collaborate on Cancer Immunotherapy Program
GeoVax Labs, Inc. recently announced it is collaborating with Vaxeal Holding SA on the expansion of GeoVax’s cancer immunotherapy program. GeoVax’s immuno-oncology program is based…
Inovio Enters License & Collaboration Agreement With ApolloBio
Inovio Pharmaceuticals, Inc. recently announced it entered an amended agreement providing ApolloBio Corporation with the exclusive right to develop and commercialize VGX-3100, Inovio’s DNA immunotherapy…
Achaogen Announces FDA Acceptance of New Drug Application With Priority Review
Achaogen, Inc. recently announced the US FDA has accepted for review the company’s New Drug Application (NDA) for plazomicin for the treatment of complicated urinary…
Sanofi & Alnylam Enter Into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance
Sanofi and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today a strategic restructuring of their RNAi therapeutics alliance to streamline and…
Enable Injections Achieves ISO Certification to Meet Mounting Demand for Drug Delivery Device Combination Products
Enable Injections, Inc., developer of the advanced enFuse large volume wearable injectors (LVWI) platform for subcutaneous delivery of biologics, has been awarded the International Organization…
BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody
BeiGene, Ltd. recently announced that in December 2017, the first patient was dosed in a global Phase 3 clinical trial of tislelizumab, an investigational anti-PD-1…
Bellerophon Announces First Patient Enrolled in Phase 2b Study
Bellerophon Therapeutics, Inc. recently announced the first patient has been randomized into a Phase 2b study evaluating INOpulse in patients with Pulmonary Hypertension associated with…
